On January 31, Fortive (FTV), a Danaher (DHR) spin-off, released its Q4 and FY2023 results and FY2024 outlook. I last reviewed FTV in this October 31, 2023 post at which time the Q3 and YTD2023 had recently been released. In addition to analyzing FTV's current results, I looked at material FTV presented at its 2023 [...]
My most recent prior Danaher (DHR) posts are entitled Danaher Consistently Generates Strong Free Cash Flow and Danaher - Current Weakness Is A Buying Opportunity. They were written following the release of Q2 and Q3 results, respectively. As noted in my October 25, 2023 post, DHR embarked on a journey to strategically enhance its portfolio [...]
Is UPS A Good Long Term Investment? Until recently, I was a shareholder since at least 2004 and categorically answer 'NO!'. I generally invest in companies with the expectation of being a very long term shareholder. Sometimes this has its drawbacks in that I hold investments far longer than I should. I last reviewed UPS [...]
I do not currently have exposure to ServiceNow (NOW) and I have never previously analyzed it. Given that it released its Q4 and FY2023 results and FY2024 outlook on January 24, I take this opportunity to analyze this company. In June 2012, ServiceNow (NOW) became a publicly traded company following a US$0.21B IPO. Since such [...]
When I last reviewed Visa (V) in my October 25, 2023 post, it had just released its Q4 and FY2023 results and FY2024 outlook. With the release of Q1 2024 results and revised FY2024 outlook following the January 25 market close, I provide this brief update. I have been a V shareholder almost from the [...]
I last reviewed Blackstone (BX) in this October 22, 2023 post at which time it had just released its Q3 and YTD2023 results. Now that BX has released its Q4 and FY2023 results on January 25, I take this opportunity to revisit this existing holding. Business Overview I encourage you to review the company's website [...]
Intuitive Surgical (ISRG) is a richly valued magnificent growth stock I last reviewed in this January 17, 2024 post following the January 9, 2024 release of certain unaudited preliminary Q4 and FY2023 financial results. In addition, it presented to the investment community at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Now [...]
I last reviewed RTX Corporation (RTX) in this October 29, 2023 post at which time it had just released its Q3 and YTD 2023 results. After reviewing the Q4 and FY2023 results and FY2024 outlook, I conclude RTX Corporation's valuation is not justified. When I completed my 2023 Year End FFJ Portfolio Review, RTX was [...]
Lockheed Martin (LMT) is advancing 21st Century security. This is one reason why it was my 7th largest holdings when I completed my 2023 Year End FFJ Portfolio Review; I hold shares in one of the 'Core' accounts within the FFJ Portfolio. In addition, LMT benefits from the U.S. Department of Defense and U.S. federal [...]
I am looking to increase exposure to Intuitive Surgical (ISRG) and its robust growth potential; it was my 15th largest holding when I completed my 2023 Year End FFJ Portfolio Review. In addition, it is currently the largest holding in a portfolio held by a young investor I am helping on their journey to [...]